Navigation Links
Celgosivir in Medical News

MIGENIX Reports Preliminary Celgosivir Viral Kinetics Study

VANCOUVER, and SAN DIEGO, Dec. 3 /PRNewswire-FirstCall/ - MIGENIX Inc. (TSX: MGI, OTC: MGIFF), a clinical-stage developer of drugs for infectious diseases, has received preliminary four-week interim results from a Phase II viral kinetics study in hepatitis C virus ("HCV") treatment-naive patie...

New Report Just Published: World Hepatitis C Virus And Therapeutics Market Report

...erferon II-58 Nautilus Biotech Commences Phase I Study for Belerofon(R) II-58 Migenix Announces Phase II Proof-of-Concept Study Results of celgosivir II-59 Pharmasset Begins Multiple Dose-Escalating Study of R7128 II-59 Transgene Commences Phase I Trial of TG4040 II-59 Debiopharm Release...
Celgosivir in Medical Technology

New Clinical Study Results Indicate Higher Early Virologic Response with Celgosivir Combination Therapy in HCV Non-Responders

Data to be Presented April 15th at EASL Conference in Barcelona, Spain VANCOUVER and SAN DIEGO, CA, April 11, 2007 /PRNewswire-FirstCall/ - MIGENIX Inc. , a clinical-stage developer of drugs for infectious diseases, has received new top-line results confirming the previously announced clinical res...

Migenix to Present Celgosivir Phase II Hepatitis C Results at Digestive Disease Week 2007

VANCOUVER and SAN DIEGO, May 18, 2007 /PRNewswire-FirstCall/ - MIGENIX Inc. , a clinical-stage developer of drugs for infectious diseases will make a presentation of results from a recent hepatitis C Phase II combination therapy study (see April 11, 2007 press release) in a non-responder patient p...

Schering-Plough Announces Hepatitis C Data Presentations at Digestive Disease Week (DDW) 2007 Annual Meeting

...bination With Peginterferon Alfa-2b in Treatment-Naive Patients With Chronic HCV; E.S. Maller, Monday, May 21, 2:15 p.m., Room 206 Phase II Study of celgosivir in combination with Peginterferon alfa-2b and ribavirin in chronic hepatitis C genotype 1 nonresponder patients; K.D. Kaita, Monday, May 21, 2:45 p.m....
Celgosivir in Biological Technology

MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study

VANCOUVER and SAN DIEGO, Jan. 31 /PRNewswire-FirstCall/ - MIGENIX Inc. (TSX: MGI, OTC: MGIFF), a clinical-stage developer of drugs for infectious diseases, will add a 600mg celgosivir combination therapy arm to its currently enrolling Phase II viral kinetics study in hepatitis C virus ("HCV") ...

MIGENIX to Present Positive Celgosivir Viral Resistance Data at International HCV Meeting

VANCOUVER and SAN DIEGO, Sept. 10 /PRNewswire-FirstCall/ - MIGENIX Inc. (TSX: MGI; OTC: MGIFF), a clinical-stage developer of drugs for infectious diseases will present results of viral resistance studies with its anti-HCV agent celgosivir at the 14th International Symposium on Hepatitis C Vir...

MIGENIX Reports First Quarter Fiscal 2009 Financial Results

...cal study program (previously Cutanea was targeting the end of 2008). celgosivir (MX-3253; oral alpha-glucosidase I inhibitor; treatment of chronic hepatiti...e are continuing to seek strategic options for advancing the development of celgosivir and are currently in key partnering discussions. MX-2401 (IV lipopeptide;...

MIGENIX Corporate Update and Requisition of Special Meeting

...ayments and a single-digit royalty on net sales. celgosivir (oral alpha-glucosidase inhibitor for Hepatitis C ...rus infections): A Phase II study assessing 400 mg celgosivir for tolerability, pharmacokinetics and viral kinet...pment by the end of 2008; to have results from the celgosivir Phase II viral kinetics study in the next several ...

Migenix Takes Operational Actions To Extend Cash Past Upcoming Key Milestones

...nt payment(s), milestones and royalty terms celgosivir (hepatitis C virus): ----------------------------... - Program-related: The planned extension of the celgosivir viral kinetics study to include a 600 mg celgosivir combination arm (600 mg ...

MIGENIX Reports Third Quarter Fiscal Year 2008 Financial Results

...such a partnership(s) is uncertain at this time. celgosivir (MX-3253; oral alpha-glucosidase I inhibitor; trea...y is currently enrolling patients to assess 600 mg celgosivir for tolerability, pharmacokinetics and viral kinet... to the standard of care drugs alone and to 400 mg celgosivir plus the standard of care for up to 12 weeks of th...

MIGENIX releases CEO message #22

...n H2/08 - NDA submission in H1/09 - Rest of world partnership celgosivir (hepatitis C virus): - Phase II viral kinetics study results (includi... application (NDA) being submitted for OmigardTM in the first half of 2009; celgosivir Phase II viral kinetic results in the third quarter 2008; CLS001 entering i...

MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results

...) for omiganan 1% gel in the first half of 2009. celgosivir (MX-3253; oral alpha-glucosidase I inhibitor; trea...ncept and evidence of clinical benefit when adding celgosivir to the current standard-of-care HCV therapy (pegyl... (SVR). The safety profile for patients exposed to celgosivir for up to 48 weeks did not differ from those in th...

MIGENIX Second Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification

... Company to Report Interim celgosivir 4-Week Viral Kinetics Study Data on Monday December ...ort interim 4-week data from a Phase II viral kinetics combination study of celgosivir in patients with chronic HCV (genotype 1) infection on Monday December 3, 2...

MIGENIX to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference

... Company Provides Revised Timing on Interim celgosivir Viral Kinetics Study ... prevention of catheter-related infections - celgosivir - a Phase II product candidate for treating chroni...rom a Phase II viral kinetics combination study of celgosivir in patients with chronic HCV (genotype 1) infectio...
Other Tags
(Date:7/28/2014)... researchers report that an alternative to the traditional handshake ... experiments, the scientists found that clasping hands transferred about ... other than what is known as a fist bump. ... a cultural substitute for the firm gripping of hands. ... of the American Journal of Infection Control . ...
(Date:7/28/2014)... Washington, DC (PRWEB) July 28, 2014 ... recipe app for iOS, App is available on iTunes for ... first of its kind, Audio Chef allows you to listen ... gourmet cuisine the easy way: simply get out the ingredients ... no need to measure or prepare ingredients ahead of time, ...
(Date:7/28/2014)... meal you,ve ordered at a restaurantor when something ... your brain. , These waves are called ... cellsboth excitatory and inhibitoryplaying together in an orchestrated ... waves have been associated with higher-level brain function, ... to schizophrenia, Alzheimer,s disease, autism, epilepsy and other ...
(Date:7/28/2014)... 28, 2014 UT Southwestern Medical Center cancer ... irreversibly interferes with the activity of a mutated ... , The molecule, SML-8-73-1 (SML), interferes with the ... homolog. The gene produces proteins called K-Ras that ... result in normal cells dividing uncontrollably and turning ...
(Date:7/28/2014)... 2014 The report, “Blowing Agents ... - Trends and Forecasts to 2019” defines and ... and forecasting of the global consumption volume and ... tables with 39 figures spread through 226 Pages ... http://www.marketsandmarkets.com/Market-Reports/blowing-agents-market-71329121.html , Blowing agents are highly utilized ...
Breaking Medicine News(10 mins):Health News:'Fist Bump' May Beat Handshake for Cleanliness 2Health News:'Fist Bump' May Beat Handshake for Cleanliness 3Health News:Audio Chef Co. Releases Audio Cooking App for iPhone/iPad/iPod touch 2Health News:Audio Chef Co. Releases Audio Cooking App for iPhone/iPad/iPod touch 3Health News:Audio Chef Co. Releases Audio Cooking App for iPhone/iPad/iPod touch 4Health News:Memory relies on astrocytes, the brain's lesser known cells 2Health News:Memory relies on astrocytes, the brain's lesser known cells 3Health News:UTSW cancer researchers identify irreversible inhibitor for KRAS gene mutation 2Health News:Blowing Agents Market is Poised to Reach 452.0 Kilotons at CAGR of 5.8% by 2019 – Report by MarketsandMarkets 2Health News:Blowing Agents Market is Poised to Reach 452.0 Kilotons at CAGR of 5.8% by 2019 – Report by MarketsandMarkets 3Health News:Blowing Agents Market is Poised to Reach 452.0 Kilotons at CAGR of 5.8% by 2019 – Report by MarketsandMarkets 4
(Date:7/28/2014)... found that 73 percent of adult survivors of childhood ... syndrome and related health problems by failing to follow ... issue of the journal Cancer . , Almost ... cancer in the study had metabolic syndrome, an umbrella ... abdominal obesity, elevated triglyceride and other abnormalities that often ...
(Date:7/28/2014)... CITY (July 28, 2014)The Brain & Behavior Research ... Klerman and Freedman Prizes, recognizing exceptional clinical and ... supported by NARSAD Young Investigator Grants. The grants ... in neurobiological and psychosocial research for the prevention, ... that affect one in four people. , Six ...
(Date:7/28/2014)... , July 28, 2014 Research and ... "Biometrics Market in Latin America 2014-2018" report to ... Biometrics measure and analyze biological data. These ... irises, eye retinas, voice patterns, and hand measurements from ... more stored templates. The main purpose of a biometrics ...
Breaking Biology News(10 mins):Unhealthy habits more than double risk of metabolic syndrome in childhood cancer survivors 2Unhealthy habits more than double risk of metabolic syndrome in childhood cancer survivors 3The Brain & Behavior Research Foundation names winners of Klerman and Freedman Prizes 2The Brain & Behavior Research Foundation names winners of Klerman and Freedman Prizes 3The Brain & Behavior Research Foundation names winners of Klerman and Freedman Prizes 4Biometrics Market in Latin America 2014-2018 2
Other Contents